Home » Stocks » OncoCyte

OncoCyte Corporation (OCX)

Stock Price: $1.62 USD -0.18 (-10.00%)
Updated Aug 11, 2020 4:00 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 108.95M
Revenue (ttm) 158,000
Net Income (ttm) -30.02M
Shares Out 67.25M
EPS (ttm) -0.51
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 11, 2020
Last Price $1.62
Previous Close $1.80
Change ($) -0.18
Change (%) -10.00%
Day's Open 1.80
Day's Range 1.62 - 1.80
Day's Volume 610,305
52-Week Range 1.20 - 3.51

More Stats

Market Cap 108.95M
Enterprise Value 99.40M
Earnings Date (est) Nov 11, 2020
Ex-Dividend Date n/a
Shares Outstanding 67.25M
Float 34.17M
EPS (basic) -0.52
EPS (diluted) -0.51
FCF / Share -0.39
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 1.74M
Short Ratio 1.19
Short % of Float 3.37%
Beta 2.55
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 689.53
PB Ratio 3.11
Revenue 158,000
Operating Income -29.98M
Net Income -30.02M
Free Cash Flow -25.47M
Net Cash 9.55M
Net Cash / Share 0.14
Gross Margin n/a
Operating Margin -18,974.05%
Profit Margin -18,879.90%
FCF Margin -16,117.72%
ROA -36.04%
ROE -82.13%
ROIC n/a
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (5)

Buy 3
Overweight 0
Hold 2
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$3.10*
(91.36% upside)
Low
1.50
Current: $1.62
High
6.00
Target: 3.10
*Average 12-month price target from 5 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013
Revenue-------
Operating Income-22.24-15.20-18.85-11.14-8.72-4.97-3.50
Net Income-22.43-15.75-19.38-11.17-8.74-4.99-3.50
Shares Outstanding51.3037.8530.2026.5321.0118.2018.20
Earnings Per Share-0.44-0.42-0.64-0.42-0.42-0.27-0.19
Operating Cash Flow-19.72-11.65-13.39-7.52-4.23-1.16-0.71
Capital Expenditures-0.92-0.03-0.09-0.11-0.50-0.01-0.03
Free Cash Flow-20.63-11.68-13.48-7.63-4.73-1.17-0.74
Cash & Equivalents22.458.468.3612.4910.543.540.00
Total Debt5.941.722.500.51---
Net Cash / Debt16.526.745.8611.9710.543.540.00
Assets39.869.5210.2214.4512.735.24-
Liabilities9.026.105.814.592.316.32-
Book Value30.843.424.409.8610.42-1.07-
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name OncoCyte Corporation
Country United States
Employees 33
CEO Ronald Asbury Andrews

Stock Information

Ticker Symbol OCX
Stock Exchange NYSE American
Unique Identifier NYSEAMERICAN: OCX

Description

OncoCyte Corporation engages in the development and commercialization of non-invasive blood-based diagnostic tests for the early detection of cancer. The company is developing DetermaVu, a non-invasive molecular lung cancer confirmatory diagnostic that is administered to patients as a blood test. It also develops diagnostic tests based on liquid biopsies for detecting breast cancer. The company was founded in 2009 and is headquartered in Irvine, California.